Author(s): Murray M,Hraiki A,Bebawy M,Pazderka C,Rawling T
Lipids have the potential for development as anticancer agents. Endogenous membrane lipids, such as ceramides and certain saturated fatty acids, have been found to modulate the viability of tumor cells. In addition, many tumors over-express cyclooxygenase, lipoxygenase or cytochrome P450 enzymes that mediate the biotransformation of ω-6 polyunsaturated fatty acids (PUFAs) to potent eicosanoid regulators of tumor cell proliferation and cell death. In contrast, several analogous products from the biotransformation of ω-3 PUFAs impair particular tumorigenic pathways. For example, the ω-3 17,18-epoxide of eicosapentaenoic acid activates anti-proliferative and proapoptotic signaling cascades in tumor cells and the lipoxygenase-derived resolvins are effective inhibitors of inflammatory pathways that may drive tumor expansion. However, the development of potential anti-cancer drugs based on these molecules is complex, with in vivo stability a major issue. Nevertheless, recent successes with the antitumor alkyl phospholipids, which are synthetic analogues of naturally-occurring membrane phospholipid esters, have provided the impetus for development of further molecules. The alkyl phospholipids have been tested against a range of cancers and show considerable activity against skin cancers and certain leukemias. Very recently, it has been shown that combination strategies, in which alkyl phospholipids are used in conjunction with established anticancer agents, are promising new therapeutic approaches. In future, the evaluation of new lipid-based molecules in single-agent and combination treatments may also be assessed. This could provide a range of important treatment options in the management of advanced and metastatic cancer.
Referred From: https://www.ncbi.nlm.nih.gov/pubmed/25603423
Author(s): Go AS, Dariush M, Véronique L, Emelia JB, Jarett DB, et al.
Author(s): Lee JH,Jarreau T, Prasad A, Lavie C, O'Keefe J, et al.
Author(s): Cicero AF,Borghi C
Author(s): Sapre S, Thakur R
Author(s): Allison DB, Antoine LH, Ballinger SW, Bamman MM, Biga P, et al.
Author(s): Lorente-Cebrián S, Costa AG, Navas-Carretero S, Zabala M, Martínez JA, et al.
Author(s): Fares H,Lavie CJ, DiNicolantonio JJ, O'Keefe JH, Milani RV
Author(s): DiNicolantonio JJ,Niazi AK, McCarty MF, O'Keefe JH, Meier P, et al.
Author(s): Kromhout D, de Goede J
Author(s): Sanders TA
Author(s): Calder PC,Yaqoob P
Author(s): Rodriguez-Leyva D,Dupasquier CM, McCullough R, Pierce GN
Author(s): Gorjão R,Azevedo-Martins AK, Rodrigues HG, Abdulkader F, Arcisio-Miranda M, et al.
Author(s): Kelley DS, Adkins Y
Author(s): Papazafiropoulou AK,Kardara MS, Pappas SI
Author(s): Burillo E, Martín-Fuentes P, Mateo-Gallego R, Baila-Rueda L, Cenarro A, et al.
Author(s): Brinson BE, Miller S
Author(s): Wachira JK, Larson MK, Harris WS
Author(s): Calder PC
Author(s): Swanson D, Block R, Mousa SA
Author(s): Kromhout D, Yasuda S, Geleijnse JM, Shimokawa H
Author(s): Grosso G,Galvano F,Marventano S,Malaguarnera M,Bucolo C, et al.
Author(s): Yates CM, Calder PC, Ed Rainger G3
Author(s): Richard D,Oszust F, Guillaume C,Millart H, Laurent-Maquin D, et al.
Author(s): VeljoviÄ M,PopadiÄ A, VukiÄ Z, IliÄ R, TrifunoviÄ Z, et al.
Author(s): Harris WS1
Author(s): Maki KC,McKenney JM, Reeves MS, Lubin BC, Dicklin MR
Author(s): Rosenfeldt F,Marasco S, Lyon W, Wowk M, Sheeran F, et al.
Author(s): Hirunpanich V, Sato H
Author(s): MacDonald L, Foster BC, Akhtar H
Author(s): Silva V,Barazzoni R, Singer P